SELLAS Life Sciences Group, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders: Jane Wasman

SELLAS Life Sciences Group, Inc.’s own tally for this item (“Elect Director: Jane Wasman”): 65,928,448 for, 5,105,730 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 The Company's stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 2,192,050 for, 127,395 withheld, 1 abstained.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders: Robert Van Nostrand

SELLAS Life Sciences Group, Inc.’s own tally for this item (“Elect Director: Robert Van Nostrand”): 66,490,143 for, 4,544,035 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 The Company's stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 2,299,280 for, 20,165 withheld, 1 abstained.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: The approval of any postponement or adjournment of the 2026 Annual Meeting, from time to time, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the 2026 Annual Meeting to adopt the proposals set forth above or to establish a quorum.

SELLAS Life Sciences Group, Inc.’s own tally for this item (“5. An adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4”): 90,571,992 for, 22,200,030 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5 The Company's stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of ”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 1,471,110 for, 848,334 against, 1 abstained.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: To approve an amendment to the Company's 2023 Amended and Restated Equity Incentive plan (the "2023 Equity Plan") to increase the number of shares of Common Stock authorized for issuance under the 2023 Equity Plan by 20,000,000 shares.

SELLAS Life Sciences Group, Inc.’s own tally for this item (“3. An amendment to the Company's 2023 Amended and Restated Equity Incentive Plan (the "2023 Equity Plan") to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000”): 42,906,271 for, 27,310,386 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 The Company's stockholders approved an amendment to the Company's 2023 Amended and Restated Equity Incentive Plan (the "2023 Equity Plan") to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000.”
Support: 61% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 2,313,925 for, 7,520 against.

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Description as filed by funds: THE ADVISORY APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SELLAS Life Sciences Group, Inc.’s own tally for this item (“4. The non-binding, advisory resolution on the executive compensation of the Company's named executive officers”): 52,930,792 for, 15,906,732 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 The Company's stockholders approved the non-binding, advisory resolution on the executive compensation of the Company's named executive officers.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 37 managers: 1,772,782 for, 546,662 against, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 110 managers: 4,305,597 for, 3,150,199 against, 2,500 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: The ratification of the appointment by our Audit Committee of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

SELLAS Life Sciences Group, Inc.’s own tally for this item (“2. The appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 112,103,701 for, 2,126,460 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 The Company's stockholders ratified the appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 2,319,433 for, 12 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.